Monoclonal antibodies in the treatment of leukemia

Susan O'Brien*, Maher Albitar, Francis J. Giles

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

MoAb-based therapies are evolving into the first broad-spectrum class of targeted anti-leukemic therapy. Developments in many areas, including computer modeling of receptors and ligands, and increasing sophistication in recombinant technologies may result in a rapid increase in the number and complexity of MoAb's available. We can anticipate an increase in the number of safer conjugates being delivered to leukemia cells. Further understanding of the in vitro mechanisms involved in tumor cell killing by MoAb will be important in maximizing the efficacy of this approach.

Original languageEnglish (US)
Pages (from-to)663-675
Number of pages13
JournalCurrent Molecular Medicine
Volume5
Issue number7
DOIs
StatePublished - Nov 2005

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology

Fingerprint Dive into the research topics of 'Monoclonal antibodies in the treatment of leukemia'. Together they form a unique fingerprint.

Cite this